August 2012
-
Inhaled epinephrine developer De Motu Cordis (DMC) announced that its CEO Peter O’Neill has stepped down and that Chief Financial Officer John Corbett will serve as Interim CEO. The company says that it is preparing… Read more . . .
-
Australian inhaled drug developer InhaleRx announced that it has received approval from the Bellberry Human Research Ethics Committee for a Phase 1 trial of its IRX-616a MDI, which the company is developing for the treatment… Read more . . .
-
According to MannKind Corporation, United Therapeutics has exercised an option granted under a 2018 licensing and collaboration agreement between the companies for development of an additional dry powder inhalation product based on MannKind’s Technosphere technology. The… Read more . . .
-
Krystal Biotech, which has been developing both injectable and inhaled formulations of its KB707 gene therapy for the treatment of solid tumors, announced that it will now focus on the inhaled therapy for the treatment… Read more . . .
-
According to BiomX, the FDA has placed a clinical hold on the company’s recently-initiated Phase 2b trial of BX004 inhaled phage cocktail in cystic fibrosis patients with chronic P. aeruginosa lung infections. BiomX said that the… Read more . . .
-
According to Boston-based CILA Therapeutics, the company has been awarded an SBIR Phase 1 grant worth almost $380,000 through the NIH’s National Center for Advancing Translational Sciences (NCATS) for pre-clinical development of the company’s CIL-Key… Read more . . .
-
Firebrick Pharma announced that the European Patent Office has accepted the company’s patent application covering the use of povidone-iodine nasal sprays, including Firebrick’s Nasodine, for the reduction of viral load of SARS-CoV-2 in the nose… Read more . . .
-
AstraZeneca has announced the launch of its FluMist Home service for delivery of the FluMist intranasal influenza vaccine in the US for the 2025-26 flu season. In September 2024, the nasal vaccine was approved by the… Read more . . .
-
Proveca and Cessatech have announced the submission of a pediatric-use marketing authorization (PUMA) application for CT001 sufentanil / ketamine nasal spray for the treatment of pain in pediatric patients and said that the EMA has… Read more . . .
-
Copley Scientific has announced the launch of its new Inhalytix+ subscription-based cascade impactor software package. The original Inhalytix software was introduced in 2021. According to the company, the new software can be integrated with testing equipment… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.